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Mosaicism of the UDP-Galactose Transporter SLC35A2
Causes a Congenital Disorder of Glycosylation
Bobby G. Ng,1 Kati J. Buckingham,2 Kimiyo Raymond,3 Martin Kircher,4 Emily H. Turner,4 Miao He,5
Joshua D. Smith,4 Alexey Eroshkin,1 Marta Szybowska,6 Marie E. Losfeld,1 Jessica X. Chong,2
Mariya Kozenko,6 Chumei Li,6 Marc C. Patterson,7 Rodney D. Gilbert,8 Deborah A. Nickerson,4
Jay Shendure,4 Michael J. Bamshad,2,4 University of Washington Center for Mendelian Genomics
and Hudson H. Freeze1,*
Biochemical analysis and whole-exome sequencing identified mutations in the Golgi-localized UDP-galactose transporter SLC35A2
that define an undiagnosed X-linked congenital disorder of glycosylation (CDG) in three unrelated families. Each mutation
reduced UDP-galactose transport, leading to galactose-deficient glycoproteins. Two affected males were somatic mosaics, suggesting
that a wild-type SLC35A2 allele may be required for survival. In infancy, the commonly used biomarker transferrin showed abnormal
glycosylation, but its appearance became normal later in childhood, without any corresponding clinical improvement. This may
indicate selection against cells carrying the mutant allele. To detect other individuals with suchmutations, we suggest transferrin testing
in infancy. Here, we report somatic mosaicism in CDG, and our work stresses the importance of combining both genetic and biochem-
ical diagnoses.Congenital disorders of glycosylation (CDGs) are a group
of more than 60 mainly autosomal recessive disorders
caused by impaired synthesis of glycoconjugates.1 Affected
individuals often have profound neurological deficiencies,
including intellectual disability, seizures, and a wide range
of multiorgan symptoms.2 The majority of CDG defects
involve the N-linked glycosylation pathway, and alter-
ations can be detected by abnormal glycosylation of the
convenient biomarker serum transferrin (Tf).3,4
All clinical samples were obtained with proper informed
consent in accordance with the Sanford-BurnhamMedical
Research Institute’s institutional review board consent
guidelines.
We identified an affected male (CDG-341) with an un-
usual Tf profile in comparison to a healthy control who
showed loss of both galactose and sialic acid frommultiple
branches of complex type N-glycans (Figures 1A and 1B).
Sanger sequencing of candidate genes encoding proteins
in the glycosylation pathway identified hemizygosity for
frameshift mutation c.15_91þ48delinsA (p.Gly8Serfs*9)
in SLC35A2 (MIM 314375, RefSeq: NM_001042498.2)
(Table 1, Figure S1A available online). This X-linked gene
encodes the single known Golgi-localized UDP-galactose
transporter. CDG-341 had a 46 XY karyotype, suggesting
that he was a somatic mosaic, given that he carried both
wild-type (WT) and mutant SLC35A2 alleles. This finding
motivated us to examine exome sequencing (ES) data
from 16 unrelated individuals with unclassified CDG and
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files similar to CDG-341 that showed loss of both galactose
and sialic acid. One of these cases (CDG-348), a female, was
heterozygous for a c.3G>A missense variant in the initia-
tion codon (p.Met1?) that eliminated the normal start
site (Table 1, Figure S1B). However, using our standard
exome filtering pipeline, we did not find any mutations
in SLC35A2 in a male individual, CDG-352, nor was he ho-
mozygous or compound heterozygous for rare variants in
known CDG-causing genes. Motivated by the unique Tf
pattern, we performed a manual review of all variants in
CDG-352 to determine whether candidate variants had
been excluded by one of the GATK filter flags. This review
revealed a c.991G>A missense variant predicted to cause a
deleterious substitution (p.Val331Ile) in the last transmem-
brane domain of SLC35A2 (Table 1, Figure S1C). This
variant had been excluded in our standard pipeline
because of a low genotype quality value of 16.99 (standard
cutoff valueR 75). Furthermore, 9% of the SLC35A2 alleles
identified in CDG-352 at the variant site were reference al-
leles, suggesting somatic mosaicism for p.Val331Ile. Sanger
sequencing confirmed this observation (Figure S1C).
None of these mutations were present in the Single
Nucleotide Polymorphism database, 1000 Genomes, or
the NHLBI Exome Variant Server (EVS), the latter of which
consists of SNVs found in >13,000 chromosomes from Eu-
ropean Americans (n ¼ 8600) and from African Americans
(n ¼ 4406). Sanger sequencing of the unaffected parents
confirmed that all of these SLC35A2 mutations arose deBurnhamMedical Research Institute, La Jolla, CA 92037, USA; 2Department
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Figure 1. Electrospray Ionization Mass Spectrometry Analyses
of Whole Serum Tf from the Control Sample and Individual
CDG-341
(A) Serum Tf from an unaffected control.
(B) CDG-341 at 5 months of age showing loss of both galactose
and sialic acid frommultiple branches of complex type N-glycans.
(C) CDG-341 at 38 months of age showing that Tf glycosylation
has become normal.novo (Table 1, Figures S1A–S1C). Collectively, these results
were compelling evidence that mutations in SLC35A2
cause a CDG subtype with unique biochemical and genetic
features.
Both affected males were hemizygous for their de novo
mutation, but they also retained a functional allele, indi-
cating somatic mosaicism for the mutant SLC35A2 allele.
This observation suggests that the retention of a functional
SLC35A2 allele might be required for survival and that
deleterious alleles might be less tolerated in males than
in females. To test this, we categorized each variant in
the NHLBI Exome Sequencing Project (ESP)6900 data set
as putatively deleterious if the variant was annotated by
SeattleSeq134 as creating a stop loss or frameshift muta-
tion or if the variant had a genomic evolutionary rate
profiling score R 3.0. To control for different numbers of
males (N ¼ 2,602) and females (N ¼ 4,190) as well as
different gene lengths, we analyzed the proportion of var-
iants in a gene that were deleterious.The AmConsistent with this hypothesis, the proportion of
SLC35A2 alleles predicted to be deleterious was both
higher in females (0.41) in comparison to males (0.25)
and ranked higher among all genes on the X chromosome
in females (358, 713th) in comparison tomales (256, 704th)
in the NHLBI ESP data set (Figure S2).
To test whether each of these variants in SLC35A2
altered galactosylation, we analyzed glycans from primary
fibroblasts and whole serum of each individual. Loss of
SLC35A2 severely limits Golgi-localized pools of UDP-
galactose, resulting in truncated b-GlcNAc-terminated
N-glycans and a-GalNAc-terminated O-glycans. These
changes predict increased binding to the lectins GSII
(Griffonia simplicifolia) for terminal b-GlcNAc on N-glycans
and to VVA (Vicia villosa) for terminal a-GalNAc on O-gly-
cans.5–7 Flow cytometry analysis with fluorescently tagged
lectins proves that all affected individual fibroblast lines fit
the predictions, indicating incomplete galactosylation,
which leads to incomplete sialylation. (Figure 2)
We directly measured the transport of UDP [6-3H]-galac-
tose into the Golgi using streptolysin-O-permeabilized fi-
broblasts to preserve intact Golgi and SLC35A2 transporter
activity.8 Despite having a mixed population of both WT
and mutant cells, all three individuals had considerably
reduced UDP-galactose transport when compared to con-
trol cells (Figure 3).
UDP [6-3H]-galactose transport assays with a 90% pure
population of CDG-341-GSII-sorted mutant fibroblasts
showed a further 20% decrease in activity and not its elim-
ination (data not shown). This supports the presence of an
alternate UDP-galactose transporter that accounts for the
activity.
Analysis of N-glycans from whole serum by MALDI-TOF
mass spectrometry also showed increased levels of hypoga-
lactosylated glycans, particularly biantennary species
(Figure S3). Given that cells from CDG-348 and CDG-341
must have either a normal allele with complete galactosy-
lation or a functionally null allele with no galactosylation
at all, the presence of a substantial amount of partially
galactosylated glycans on serum glycoproteins further
suggests the possible existence of a previously unrecog-
nized UDP-gal transporter.
Other studies suggest that a normal UDP-GlcNAc trans-
porter, SLC35A3 [MIM 605632], can also improve galacto-
sylation in the UDP-galactose-deficient CHO cell line
LEC8. Furthermore, many putative nucleotide sugar trans-
porters are incompletely characterized.9
The clinical phenotypes and severity of biochemical
defects of these individuals varied substantially (Table 1).
Nevertheless, at 5–7 months of age, all individuals had
similar galactosylation-deficient Tf profiles; but a sample
obtained from CDG-348 at 3 years of age showed a nearly
normal pattern without clinical improvement (Figure S4).
Samples taken at an older age in both CDG-352 (5
years of age) and CDG-341 (3 years of age) (Figure 1C)
were also completely normal. This normalization in all
three individuals suggests that SLC35A2-CDG caseserican Journal of Human Genetics 92, 632–636, April 4, 2013 633
Table 1. Clinical Presentation and SLC35A2 Mutations Identified in Three Families with CDG Type IIx
CDG-341 CDG-348 CDG-352
Ancestry European European European
Gender Male Female Male
Current Age 3 years 3 years 6 years
Inheritance de novo de novo de novo
Nucleotide Change chrX:
48,768,775_48,768,899
delinsT
chrX:
48,768,911
C>T
chrX:
48,762,195
C>T
cDNA Change c.15_91þ48 delinsA c.3G>A c.991G>A
Protein Change p.Gly8Serfs*9 p.Met1? p.Val331Ile
Likely Affect on Protein Termination Loss of initiator methionine Improper positioning in membrane
Developmental Delay Yes Yes Yes
Hypotonia Yes Yes Yes
Seizures Yes Yes No
Hypsarrhythmia Yes Yes No
Hypertension No No Yes
Dysmorphic features No Yes Yes
Skeletal abnormalities No Shortened extremities Shortened extremities
Renal No No Acute nephrotic syndrome; requiring dialysis
Ocular Nystagmus Retinitis pigmentosa Ocular flutter
Liver dysfunction No No No
Coagulopathy Yes No No
Gastrointestinal No Strictly G-tube feed Gastro-esophageal reflux, esophagitis,
duodenal perforation
Recurrent Infections No Yes No
Microcephaly No Yes Yes
Brain malformation Small cerebellum Thinning of corpus callosum with
delayed myelinization
Cerebral hypoplasia/atrophycould have a limited abnormal Tf diagnostic window,
and, without that biochemical lead, standard exome
analysis would have discounted the complex results
from these somatic mosaics. Accordingly, individuals
suspected of having a CDG should be tested for abnormal
Tf as early in life as possible. In each individual, it is very
likely that Tf testing would have been normal had
it been delayed, making diagnosis of a CDG much more
challenging.
One explanation for the normalized Tf profiles is that
hepatocytes carrying the mutant allele are selected against
during infancy. In support of this, we found that GSII-
enriched fibroblasts (CDG-341) containing the mutant
allele grew ~25% slower than cells with a WT allele (data
not shown). Moreover, DNA prepared from peripheral
blood leukocytes had nearly undetectable levels of the
mutant allele (data not shown). Again, this suggests
possible selection against abnormal cells.
We tried to improve galactosylation in each fibroblast
line by providing 150–300 uM galactose for between 2–634 The American Journal of Human Genetics 92, 632–636, April 4, 24 days, but we saw no significant improvement in GSII
binding.
Our study highlights the importance of combining
biochemical data and detailed knowledge of glycosylation
pathways to narrow the candidate genes from ES. We
suggest that this approachwill help solve theother glycosyl-
ation disorders, even if Tf was not analyzed or was uninfor-
mative. Heightened awareness of glycobiology and the
accelerating discovery of new glycosylation disorders by ES
will enhance both basic science and medical practice.10,11
Supplemental Data
Supplemental Data include four figures and can be foundwith this
article online at http://www.cell.com/AJHG.Acknowledgments
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Figure 2. Cell-Surface Analysis of Defi-
cient Galactosylation and Increased Ter-
minal b-GlcNAc and a-GalNAc
(A) Flow cytometry analysis of Alexa-647-
conjugated GSII (Griffonia simplicifolia) lec-
tin in control and individual fibroblasts
showing increased lectin binding in all
three individuals. The parallel control is
representative of three different lines that
were tested.
(B) Flow cytometry analysis of fluorescein-
labeled VVA (Vicia Villosa) lectin in control
and individual fibroblasts also showing
increased binding in all three individuals.
The parallel control is representative of
three different lines that were tested.
Figure 3. SLC35A2 Transport Activity in Fibroblasts from Both
Control and Affected Individuals
Golgi transport of UDP [6-3H]-galactose in streptolysin-O permea-
bilized fibroblasts from controls and affected individuals. Each
data point was done in duplicate, and error bars were calculated
by SD.
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